(Q24186444)

1

0 references

Nathan Herrmann

2

0 references

Myuri T Ruthirakuhan

3

0 references

Jinghan Jenny Chen

Cochrane Database of Systematic Reviews

4

0 references

publication date

21 April 2015

0 references

published in

0 references

cites work

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

2010 Alzheimer's disease facts and figures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

21 January 2018

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

7 January 2021

inferred from DOI database lookup

Use of the EQ-5D among patients suffering from dementia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Mitochondria as a target for neurotoxins and neuroprotective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Cholinesterase inhibitors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Forecasting the global burden of Alzheimer’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

21 January 2018

Dimebon disappointment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Alzheimer's disease: clinical trials and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

21 January 2018

Memantine for dementia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Recent developments in Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

What is the clinically relevant change on the ADAS-Cog?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Evaluation of Dimebon in cellular model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009524.PUB2

Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.

21 January 2018

1 reference

12 December 2020

Sites of phosphorylation in tau and factors affecting their regulation.

1 reference

12 December 2020

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

12 December 2020

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

12 December 2020

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

12 December 2020

Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer

1 reference

12 December 2020

The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease

1 reference

12 December 2020

Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis.

1 reference

12 December 2020

The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia

1 reference

12 December 2020

Dimenhydrinate effect on cerebral oxygen status and salivary chromogranin-A during cognitive tasks

1 reference

12 December 2020

Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.

1 reference

12 December 2020